Weitnauer attorneys Hans-Eric Rasmussen-Bonne and Tim Kowalsky served as counsel to Advanced BioInformatics GmbH (ABI) on the conclusion and implementation of a share purchase agreement and an exclusive licensing agreement with the University of Utah intending to develop novel cardiac rhythm management solutions based on proprietary low-energy pacing technology.
ABI is an international medical technology company working to develop next-generation cardiac management solutions for patients with significantly fewer complications and side effects than current standards of care.
“We look forward to efficiently advancing our pre-clinical work and initiating formal clinical studies as expeditiously as possible while in parallel exploring partnering opportunities with leading implantable cardiac defibrillator manufacturers around the world,” said J. Todd Derbin, Managing Director and Co-Founder of ABI.
“We believe an unmet medical need exists with these patients who desire a better therapeutic option, and we plan to work diligently toward that goal,” added ABI Managing Director and Co-Founder Volker Brand.
Weitnauer has already advised the company on the foundation, on an employee participation program and on IP issues.